C-P5VFsmall-molecule oral therapy, synapse protection, toxic oligomer blockade
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cognition Therapeutics small-molecule oral therapy, synapse protection, toxic oligomer blockade
Cognition Therapeutics is developing therapies designed to help patients and caregivers living with age-related neurodegenerative diseases. Its investigational first-in-class therapy zervimesine (CT1812) is described as a once-daily small-molecule oral therapy designed to protect brain synapses before irreversible neuronal decline occurs. The site highlights dementia with Lewy bodies and Alzheimer’s disease as areas of focus.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Cognition Therapeutics — Translational · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (3 programs at…
Source: Deterministic